

The logo for amoéba features three overlapping, curved shapes in blue, green, and light green, resembling a stylized amoeba or a circular graphic. A thin white horizontal line passes through the center of the logo and the text.

amoéba

January 2025 | Investors Presentation

YOUR CONTACTS

A new dynamic driven by a united team with solid experience in international environments



Benoit VILLERS

Chairman of the Board of Directors

Since December 2023

- Member of senior management at Barry Callebaut and ADM for over 21 years
- Co-Founder of Nice & Green



Jean-François DOUCET

CEO and Chief Financial Officer

Since May 2023

- 30 years' experience in management and finance
- Expertise in operations and strategy in the health and chemicals sectors, in commercial, industrial and international environments

A LYON-BASED GREENTECH

Listed on Euronext Growth

Amoéba

Created in 2010, Amoéba is a french greentech specializes in the development of natural microbiological solutions based on the patented use of amoebas.

Some figures

2

Business focus:
biocontrol and
cosmetics

1

Development
platform

39


Patents

1

Production unit in
Chassieu (France)

20

Employees



AMOÉBA CHRONOLOGY

From an R&D company to a Commercialization company

● 2010

Creation of Amoéba

13 years of R&D to become the only company in the world capable of producing amoeba on an industrial scale

● 2015

Initial public offering

Euronext Growth

● 2023

Start of the transformation of an R&D company into an industrial and commercial company

Renewed governance, with stronger support from a major shareholder

● 2024

Cosmetics: proven effectiveness

Scientific and clinical results for anti-ageing effects

●

Biocontrol: the road to market

Memorandum of understanding for collaboration with a world leader (Koppert) signed on 12.12.2024 and receipt of positive and definitive conclusions from EFSA on 13.12.2024

● 2025-26

Biocontrol and cosmetics

Sales start-up scheduled, costs and investments under control

● 2027



Positive EBITDA

THE AMOEBA, DEFINITION AND SPECIFIC FEATURES

An amoeba

A naturally occurring unicellular microorganism found in all environmental compartments, particularly in humid environments, including the human body.

At present, there are over 17,000 known amoebae, but they remain unexploited, apart from the one for which Amoéba has developed patented applications.



Our amoeba

Origin

W. magna C2C Maky **biosourced** in Aix-les-Bains thermal spring water, and **secure storage**

Innovation

The only company in the world capable of cultivating amoeba

Forms of use

Available in live or lysed form (fractionated amoeba)

Safety

- **No toxicity** for human
- **No ecotoxicity** demonstrated by tests and studies


Composition

- Contains 74% of proteins
- 50% of proteins are unknown to the scientific world

Amoéba is the only company with patented applications and unique know-how to cultivate amoeba in sufficient volumes for industrial and commercial use, giving it a lead of at least 10 years.

A TECHNOLOGICAL PLATFORM WITH MULTIPLE APPLICATIONS

2 pre-marketing ranges



AXPERA

Our range of solutions for the transition from chemical to organic production

Positive impact on agriculture



A highly competitive level of **performance**, demonstrated by over 600 field trials carried out in 19 countries

A natural product that meets the requirements of sustainable agriculture for **a wide range of crops:**



- Under glass: tomatoes, cucumbers, etc.
- Open fields: vines, soya, etc.
- Public areas: golf courses, gardens ...




European **market** estimated at **€1.6 billion**, growing at +/- 10% / year and US market estimated at **€3 billion**, growing at +/- 15% / year until 2030

Market launch targeted for 2025



Regulatory

Positive and definitive conclusions on the active substance in the United States and Europe, before registration of products targeted in 2025.



Production

Gradual increase in production capacity (from 0.5 tonnes to 10 tonnes) at Chassieu for commercial launch and negotiation of a CDMO (production partnership) with Koppert.



Distribution

Memorandum of Understanding (MoU) signed with Koppert, world leader in biocontrol.

THE IDEAL SOLUTION

To reduce the use of copper

Context

Copper is widely used to combat mildew, but its use poses environmental problems. From 2025, European regulations will continue to reduce the use of copper in agriculture.


Solution: Axpera

- Example of the trial: combined with copper, Axpera reduces the amount of copper used by 83%, while maintaining the same efficacy as copper at full dose.
- Improved efficacy: Axpera, in combination with a chemical product, is **as effective as, or even more effective**, than the chemical product alone.

This ability to be combined with other products is a major advantage when it comes to establishing commercial partnerships.

Distributors, who are often reluctant to simply replace a chemical product, can be convinced of the benefits of incorporating Axpera into their offering.

Efficacy on powdery mildew for tomatoes



POSITIVE ASSESSMENT BY THE EFSA

A determining milestone now completed



The European Food Safety Authority (EFSA) is one of the European Union's main agencies responsible for risk assessment in the field of foodstuffs.

What does the EFSA say?

- ✓ Proven fungicidal efficacy;
- ✓ A low-risk profile for human and animal health, as well as for ecosystems and environmental organisms;
- ✓ The criteria for exemption from a maximum residue level have been met.

The European Commission has an administrative period of 6 months to approve the active substance.

AMOÉBA x KOPPERT (1/2)

Signature of a Memorandum of understanding

The start of a collaboration with a world leader in biocontrol

Koppert offers "a system of specialist knowledge and safe natural solutions to improve the health, resistance and production of crops".



Why partner together ?

- ✓ **Mutual expertise:** Koppert, a global leader in biocontrol, has conducted a thorough due diligence of Amoéba over two years trials, confirming the efficacy of its solutions.
- ✓ **Perfect synergy:** Amoéba's innovative fungicides complement Koppert's portfolio.
- ✓ **Shared vision:** Both companies are driven by innovation, sustainability, and natural ingredients.


Together, we will leverage Koppert's 2,750 employees, 30 subsidiaries, 20% annual growth, and distribution in over 100 countries to deliver sustainable agricultural solutions worldwide.

AMOÉBA x KOPPERT (2/2)

Signature of a Memorandum of understanding

A new milestone for Amoéba

- ✓ A MoU have been signed at the end of 2024
- ✓ 5-Month Exclusive Negotiation to explore the various aspects of global cooperation:



Distribution



Production



**Regulatory
authorisations**



Financing



**Co-development
of new products**

SKIN PROTECTION (ANTI-AGEING / ANTI-UV)

A recent and promising innovation with proven effects


October 2023 - Remarkable in-vitro studies

Anti-ageing effect


| | Filaggrin | Loricrin | Ki67 | COL VII | HA (Dermis) | HA (Epidermis) | HA (Total skin) |
|-------------------|-----------|-----------|------------|------------|-------------|----------------|-----------------|
| Young skin | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Aged skin | 19 | 67 | 66 | 4 | 95 | 74 | 73 |
| Treated aged skin | 87 | 99 | 112 | 265 | 107 | 123 | 101 |

Anti-UV effect


Young skin irradiated with UV




Young skin **treated** and then irradiated with UV light



A restored skin structure



Mature untreated skin



Mature skin **treated**

SKIN PROTECTION (ANTI-AGEING / ANTI-UV)

A recent and promising innovation with proven effects

May 2024 – the clinical study confirms excellent in-vitro tests

Results of clinical trials justifying very strong claims in the field of anti-ageing cosmetics:

- "improvement in the thickness of the dermis"
- "repairing effect on the superficial dermis"
- "improved dermal texture"
- "improved skin density"
- "improved skin firmness and radiance"
- "improved skin texture and elasticity"
- "anti-wrinkle"

Wrinkle reduction after 28 days



Photos of the Institute for Clinical Expertise (IEC) in Lyon, taken with the professional camera opposite:



Newton Technologies

SKIN PROTECTION (ANTI-AGEING / ANTI-UV)

A recent and promising innovation with proven effects

2023

Brevet

Filing of a patent to protect the use of amoeba as a cosmetic ingredient

2024

INCI

Inclusion of our cosmetic ingredient on the INCI (International Nomenclature of Cosmetics Ingredients) list of products, which means it can be marketed without further approval

2025

Label Cosmos approved

Label certifying the natural origin and eco-friendly ingredient

2025-26

Developpement

- Business development agreement(s)
- Product testing and development : (formulation testing, range creation, etc.)
- Expansion of our active ingredient range with independent formulators (combination of patented ingredients)

2026-27

Production et commercialisation

Production and marketing of the ingredient

A COMPAGNY WITH STRONG SUPPORT

Board of Directors



Benoit VILLERS
Chairman



Valérie LORENTZ-POINSOT
Ex-CEO Laboratoires Boiron



Quentin HUA
Laboratoires Boiron



Patrice SELLES
Former Executive at Syngenta
Ex-CEO Biotalys



Jean-Luc SOUCHE
Ex Director at Amoéba




Jean-Marc PETAT
Former Executive of BASF
Agro-France



Valérie FILIATRE
Ex-Deputy General
Manager of Amoéba

Shareholder structure



■ Floating ■ Nice & Green

Market capitalisation: €47m

SCALABLE INDUSTRIAL CAPACITIES

A strategy to minimize direct investments



2024

Existing line in Chassieu.
Current capacity of **0.5 tonne** active substance per year.



2025-26


Capacity increase in 3 phases at Chassieu.
Gradual increase from **0.5 tonne to 10 tonnes** of active substance per year. Capacity equivalent to > **40,000 ha** for crop treatment and very sufficient for the cosmetics business.



2026

Priority given to finding a production partnership (**CDMO**) to support the ramp-up in sales without massive additional investment.

LEGAL REORGANIZATION PROJECT



Listed company


- R&D
- Production
- Support services

Operating companies

- By activity

A PROFITABLE COMPANY FROM 2027

Two complementary markets to optimise the platform's current potential and diversify risks



WHY INVEST

The only company dedicated to growing amoebas

Unique technological expertise

- ✓ The only company in the world capable of growing amoebae on an industrial scale.
- ✓ Exclusive technology enabling the amoeba to live and multiply.

Worldwide exclusivity

- ✓ The only private company in the world to exploit the positive applications of amoeba.
- ✓ An innovative alternative to the hundreds of companies working with other resources.
For example: proteins, algae, etc.

Leading position

- ✓ Competitive advantages thanks to unique specialisation and expertise.
- ✓ Several years ahead of potential competitors.

Growth potential


- ✓ Areas that range from agriculture to cosmetics, with potential openings in other sectors such as medical.
- ✓ Approvals obtained in the USA, in the process of being concluded in Europe (validation obtained by EFSA).

WHY INVEST NOW ?

A financial market rediscovering Amoéba

- **2015**
Initial public offering
(Euronext Growth)
- **+140%**
Positive share price
trend in 2024
- **47 M€**
Market
capitalization
- **161 k€**
Average daily volume
(since 1/10/2024)

Share price in 2024



Cours de bourse d'Amoéba du 29.12.2023 au 31.12.2024



Amoéba



amoeba-nature.com



amoeba@actus.fr

DISCLAIMER

References herein to this presentation (the “Presentation”) shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the “Company”), any question-and-answer session following that oral presentation and any further information that may be made available in connection with the subject matter contained herein.

This Presentation has been prepared by the Company and is for information only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on the multilateral trading facility of Euronext Growth, including, in particular, the risk factors set out in the universal registration document (the “URD”) filed with the French Financial Markets Authority (Autorité des marchés financiers) (the “AMF”) on April 18, 2023 under number D.23-0296, and in any other periodic report, which are available free of charge on the websites of the Company (<https://amoeba-nature.com>) and the AMF (www.amf-france.org). Information and other data appearing in such publications, and certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually rounded figures, amounts or percentages.

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this Presentation, or its use for any purpose, and no reliance should be placed on any information or opinions contained herein. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained in it. In particular, this document contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company’s own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisors concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any investment decision.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised or amended, and thus such information is subject to change at any time. Neither the Company, its subsidiaries, directors, officers, employees, agents, affiliates nor its advisors, nor any other person is under any obligation to update the information, statements or opinions contained in this Presentation. Nothing contained in this Presentation is or should be relied upon as a promise or representation as to the future.

All statements in the Presentation other than statements of historical fact are or may be deemed to be forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of known and unknown risks and uncertainties. These risks and uncertainties, and other factors, could adversely affect the outcome of the forward-looking statements, and actual results could differ materially from those contemplated in the statements. As a result, you are cautioned not to rely on such forward-looking statements. Forward-looking statements speak only as of the date of this document and the Company expressly disclaims any obligation or undertaking to update or re-issue any forward-looking statements contained in this Presentation.

This Presentation does not constitute or form any part of any offer to sell, or the solicitation of an offer to buy or subscribe for, any shares or securities in the Company, in the United States or in any other jurisdiction.

All persons accessing this document are deemed to agree and comply with all the limitations and restrictions set out above.